Tag Archives: COPD

FLUIDDA’s FRI Technology was used in a Positive Phase II Trial with iNOpulse® for Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)

“Functional Respiratory Imaging (FRI) provided valuable insights throughout the development process of iNO in COPD patients with PH. The therapy was effective in the initial studies and has great potential to improve the lives of these severely affected patients”

Dr. J. De Backer, CEO FLUIDDA

 

Changes in Blood Vessel Volume determined using Functional Respiratory Imaging (FRI)

The Phase 2 study was designed to assess the acute effect of pulsed inhaled nitric oxide (iNO) on targeted vasodilation and the chronic effect (4 weeks) of iNO on hemodynamics and exercise capacity.  The study enrolled 10 subjects and used a dose of 30 mcg/kg IBW/hr (iNO 30).  The acute results showed a statistically significant increase (average 4.2%) in blood vessel volume  on iNO compared to baseline (p=0.03), and a statistically significant correlation in Ventilation-Vasodilation (p=0.01), indicating targeted delivery to the well-ventilated alveoli. Both blood vessel volume changes and ventilation-vasodilation relations were measured using Functional Respiratory Imaging (FRI). The chronic results demonstrated statistically significant and clinically meaningful increases in six-minute walking distance (6MWD) at both 2 weeks and 4 weeks (+50.7m; p=0.04), as compared to baseline.  In addition, the study demonstrated a statistically significant and clinically meaningful decrease of 19.9% in systolic pulmonary arterial pressure (sPAP) at 4 weeks (p=0.02), as compared to baseline.  The therapy was well tolerated with no related safety concerns.

Read more here

 

 

FLUIDDA’s FRI technology will shine throughout ERS 2017

As the European Respiratory Society Conference is approaching rapidly, FLUIDDA is proud to announce that a total of 9 abstracts will be presented, highlighting the power of Functional Respiratory Imaging (FRI). FRI capabilities will be presented over a range of applications including: drug delivery optimization bronchodilation and non-invasive ventilation in COPD bronchoconstriction in asthma disease… Continue Reading

Study demonstrates validity and utility of FRI-based V/Q

Exciting new results will be presented at the upcoming European Respiratory Society Conference in Milan from 9-13 September! The primary function of the respiratory system is the transfer oxygen from the environment into the blood stream of a individual. Consequently in a healthy subject the regional ventilation in the lungs is well matched to the… Continue Reading

ATS 2016 : FLUIDDA presents 7 abstracts in the scientific program.

FLUIDDA’s mission: improving the health of respiratory patients ATS 2016 contribution: 7 abstracts in the scientific program. Tuesday, May 17, 2016 Room 304 (South Building, Esplanade Level): Session C23: 9:00 AM-11:00 AM Poster Discussion: Contemporary Questions in Lung Transplantation Assessment of FEV1 decline after lung transplantation using Functional Respiratory Imaging Area D, Hall D, P406… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017